Intellectual property, drug licensing, freedom of information, and public health
- 1 August 1998
- journal article
- public health
- Published by Elsevier in The Lancet
- Vol. 352 (9129) , 726-729
- https://doi.org/10.1016/s0140-6736(98)07600-4
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Review sparks controversy over human albumin therapyThe Lancet, 1998
- Meeting the challenges facing research ethics committees: some practical suggestionsBMJ, 1998
- Too soon to marketBMJ, 1997
- Secrecy in drug regulationInternational Journal of Risk & Safety in Medicine, 1996
- Does Research Synthesis Have a Place in Drug Regulatory Policy? Synopsis of Issues: Assessment of Efficacy and Drug ApprovalClinical Research and Regulatory Affairs, 1996
- Ethical imperative to publish extends to academics tooBMJ, 1995
- Effect of albumin supplementation during parenteral nutrition on hospital morbidityCritical Care Medicine, 1988
- Study of information submitted by drug companies to licensing authorities.BMJ, 1980